Antiviral Therapy for Influenza A H1N1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

181 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of this study are to characterise the clinical efficacy and virological clearance dynamics of orally administered oseltamivir in patients with influenza caused by novel influenza A(H1N1). This research will also contribute to enhancing research capacity in affected countries.

The objectives are to assess the:

* viral replication levels over time in affected patients
* antiviral efficacy of oral oseltamivir
* patterns and compartments of viral shedding, tissue distribution
* innate inflammatory response and relation to viral replication
* kinetics of antibody response
* antiviral sensitivity of influenza viruses at baseline and during oseltamivir treatment using in vitro and molecular methods
* pharmacokinetic characteristics of oseltamivir and oseltamivir carboxylate
* all cause in hospital mortality
* clinical and radiological features, disease course and outcome
* length of stay in hospital
* risk factors associated with development of severe disease and death

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza

NCT01052961

Influenza Respiratory Tract Infections

COMPLETED PHASE4

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

NCT01314911

Influenza, Human

COMPLETED NA

Oseltamivir Randomised Controlled Efficacy Trial

NCT00707941

Influenza Pneumonia Lower Respiratory Tract Infection +2 more

COMPLETED PHASE3

Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age

NCT01037634

Influenza

WITHDRAWN PHASE2

Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age

NCT00593502

Influenza

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Any patient over 1 year of age who presents to a participating institution with confirmed influenza A and who meets the study inclusion/exclusion criteria may be approached for informed consent. Choice of antiviral is up to the study physician. Children aged 1-6 years and asthmatics should receive oseltamivir. The weight- and age-adjusted dosage used will be that approved for treatment of uncomplicated seasonal influenza, and doses will be administered twice daily for 5 days for patients with normal renal function. All patients who are clinical and/or virologic failures at day 5 will be treated for an additional 5 days of antivirals. After coming off antiviral therapy patients can be discharged at day 10 if deemed ready by study physicians and they are virologically negative.

During the course of treatment study evaluations will be performed to determine primary efficacy end points including viral clearance on Day 5 on all collected nasopharyngeal samples, assessed by RT PCR for novel H1N1 influenza AND no clinical features of clinical failure. Evaluations will also be performed to determine secondary viral, serological, clinical efficacy, safety and pharmacokinetic endpoints.

Patients will be followed up for up to 6 months after discharge for a clinical assessment, pulmonary function and outcome of pregnancy.

The protocol will be reviewed after 6 months from starting or after 100 patients with Influenza A are recruited.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza A Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults, including pregnant and breast feeding women, and Children aged ≥ 12 months when first seen with an acute febrile respiratory tract illness (ARI) of any severity and influenza A, virologically proven on a respiratory specimen according to hospital procedure, which is suspected to be novel influenza A(H1N1)
* A positive influenza A H1 swine screening reverse transcriptase polymerase chain reaction (RT PCR) or conventional PCR assay on one respiratory specimen : NPA, NP swab, nasal wash, nasal swab and throat swab
* Underlying illnesses including HIV
* Prescribed oseltamivir prior to presentation